newsfilter
← Latest News
GlobeNewswire·

BiondVax Announces Pricing of $8 Million Underwritten Public Offering

JERUSALEM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) ("Company"), which focuses on developing, manufacturing, and commercializing innovative immunotherapeutic